Timothy Keutzer sold $3,339 of SPRO
Chief Operating Officer at Spero Therapeutics, Inc.. 1,695 shares at an average of $1.97, traded Aug 28, 2025, filed Sep 3, 2025.
Score components
- +20RoleCOO
- 0Trade size$3k at market
- 0Share of holdings soldSold 0.2% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-112659, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 28, 2025 | SOpen-market sale Common Stock | -1,695 | $1.97 | $3,339 | 739,744 | Sep 3, 2025 |
Related signals
Other insiders at Spero Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | SPROsell Spero Therapeutics, Inc. | Esther Rajavelu See Remarks | $95k 40,270 shares | -4% | |
| 23Weak | Spero Therapeutics, Inc. | Ankit Mahadevia director | $13k 6,572 shares | -1% | |
| 26Weak | SPROsell Spero Therapeutics, Inc. | Timothy Keutzer Chief Operating Officer | $44k 56,537 shares | -7% | |
| 29Weak | SPROsell Spero Therapeutics, Inc. | Esther Rajavelu CFO & CBO | $53k 40,596 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.